Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy encouraging results of a preliminary study

Evidence-based Complementary and Alternative Medicine

Volumn 7, Issue 1, 2010, Pages 129-136

  Banerjee, Antara ^a   Chakrabarty, Sudipa Basu ^b   Karmakar, Susanta Roy ^a   Chakrabarty, Amit ^b   Biswas, Surjyo Jyoti ^a   Haque, Saiful ^a   Das, Debarsi ^a   Paul, Saili ^a   Mandal, Biswapati ^c   Naoual, Boujedaini ^d   Belon, Philippe ^d   Khuda Bukhsh, Anisur Rahman ^a  

^a UNIVERSITY OF KALYANI   (India)

^b Institute of Genetic Engineering   (India)

^c BIDHAN CHANDRA KRISHI VISWAVIDYALAYA   (India)

^d Boiron   (France)

Author keywords

Ceanothus Americanus; Ferritin; Ferrum Metallicum; Fetal hemoglobin; Homeopathic remedy; Hydroxyurea; Pulsatilla Nigricans; Thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CEANOTHUS AMERICANUS EXTRACT; FERRITIN; FERRUM METALLICUM; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; IRON DERIVATIVE; PLACEBO; PLANT EXTRACT; PULSATILLA NIGRICANS EXTRACT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CEANOTHUS; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HOMEOPATHY; HUMAN; LEUKOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN SIZE; THALASSEMIA; THROMBOCYTE COUNT; TINCTURE; TREATMENT DURATION;

EID: 77249176586     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem161     Document Type: Article

References (43)

1. Rund D, Rachmilewitz E. b-Thalassemia. N Engl J Med 2005;353:1135-1146
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of b-thalassemia major in North America. Blood 2004;104:34-39
3. Higgs DR, Thein SL, Woods WG. The pathophysiology of the thalassemias. In: Weatherall DJ, Clegg B (eds). The Thalassemia Syndromes, 4th edn. Oxford, England: Blackwell Science, 2001, 133-191
4. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
5. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193
6. Wanless IR, Sweeney G, Dhillon AP, Guido M, Pig A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusiondependent b-thalassemia. Blood 2003;101:2460.
7. Ceci A, Baiardi P, Felisi M, Capellini MD, Carnelli V, De Sanctis V, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336
8. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489-496
9. Hershko C, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep 2005;4:110-116
10. Anderson LJ, Wonke B, Precott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002;360:516-520
11. Cohen AR, Galanello R, Pannell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology (Am Soc Hematol Educ Program) 2004;1:14-34.
12. Gallo E, Massero P, Miniero R, David D, Tarella C. The importance of the clinical and hematological features of thalassemia intermedia. Blood 1979;41:211-221
13. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and b-thalassemia. Semin Hematol 2001;38:367-373
14. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;290:756.
15. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, Montalembert MD. Hydroxyurea can eliminate transfusion requirements in children with severe b thalassemia. Blood 2003;102:1529-1530
16. Sylvia ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, et al. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E/b0 thalassemia: Considerations for treatment. Ann N Y Acad Sci 2005;1054:250-256
17. Watanapokasin Y, Chuncharunee S, Sanmund D, Kongnium W, Wnichagoon P, Rodgers GP, et al. In vivo and intro studies of fetal hemoglobin induction by hydroxyurea in b thalassemia/hemoglobin E patients. Exp Hematol 2005;33:1486-1492
18. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusiondependent b thalassemia patients. Haematologica 2004;89:1172-1178
19. Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal G gamma globin production. Blood 1985;66:783-787
20. Fucharoen S, Siritanaratkul N, Winichagoon P, Gowthaworn J, Siriboon W, Maaungsup W, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in b-thalassemia/Hemoglobin E disease. Blood 1996;87:877-892
21. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major b thalassemia and importance of genetic screening. Ann Hematol 2004;83:430-433
22. Watanapokasin R, Sanmund D, Wnichagoon P, Muta Koichiro, Fuchareon S. Hydroxyurea responses and fetal hemoglobin induction in b thalassemia/Hb E patients peripheral blood erythroid cell culture. Ann Hematol 2006;85:164-169
23. Rachmilewitz EA, Aker M, Perry D, Dover G. Sustained increase in hemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous bthalassemia. Br J Haematol 1995;90:341-345
24. Fibach E. Cell culture and animal models to screen for promising fetal hemoglobin-stimulating compounds. Semin Haematol 2001;38:374-381
25. Oliveiri NF, Rees DC, Ginder GD, Thein SL, Wayne JS, Chang L, et al. Elimination of transfusions through induction of fetal hemoglobin synthesis in Colley's anemia. Ann N Y Acad Sci 1998;850:100-109
26. Perrine SP. Fetal globin induction-can it cure b thalassemia? Hematology 2005;38-44.
27. Clarke JH. A Dictionary of Practical Materia Medica, Vol.III. New Delhi, India: B. Jain Publishers (P) Ltd, 2003.
28. Choudhuri NM. A Study on Materia Medica. New Delhi, India: B. Jain Publishers (P) Ltd, 1999.
29. Fuchareon S, Winichagoon P, Wisedpanichikij R, Sae-Ngow B, Sriphanich R, Oncoung W, et al. Prenatal and postnatal diagnoses of thalassemias and hemoglobinopathies by HPLC. Clin Chem 1998;44:740-748
30. Oliveiri NF, Weatheral DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 1998;7:1655-1658
31. Cao A, Gatanello R, Rosatelli MC. Genotype-phenotype correlations in b-thalasemia. Blood Rev 1994;8:1-12.
32. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322
33. Olivieri NF. Reactivation of fetal hemoglobin in patients with beta thalassemia. Semin Hematol 1996;33:24-42.
34. Veith R, Galanello R, Papayannopoulou G, Stamatoyannopoulos G. Stimulation of F-cell production patients with sickle cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985;313:1571-1575
35. Maier-Redeiersperger M, De Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP. Fetal hemoglobin and Fcell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 1998;91:4472-4479
36. Hajjar FM, Pearson HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994;125:490-492
37. Dixit A, Chatterjee TC, Mishra P, Choudhury DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol 2005;84:441-446
38. Khuda-Bukhsh AR. Potentized homeopathic drugs act through regulation of gene-expression: a hypothesis to explain their mechanism and pathways of action in vivo. Comp Ther Med 1997;5:43-46
39. Khuda-Bukhsh AR. Towards understanding molecular mechanisms of action of homeopathic drug: an overview. Mol Cell Biochem 2003;253:339-345
40. Khuda-Bukhsh AR. Laboratory research in homeopathy: pro. Integr Cancer Ther 2006;5:320-332
41. Khuda Bukhsh AR, Pathak S, Guha B, Roy Karmakar S, Das JK, Banerjee P, et al. Can homeopathic arsenic remedy combat arsenic poisoning in human exposed to ground water arsenic contamination: a preliminary report on first human trial. Evid Based Complement Alternat Med 2005;2:537-548
42. Belon P, Banerjee P, Chaki Choudhury S, Banerjee A, Biswas SJ, Roy Karmakar S, et al. Can administration of potentized homeopathic remedy, Arsenicum Album, alter anti-nuclear antibody (ANA) titer in people living in high risk arsenic contaminated areas?: I. A correlation with certain hematological parameters. Evid Based Complement Alternat Med 2006;3:99-107.
43. Belon P, Banerjee A, Roy Karmakar S, Biswas SJ, Chaki Choudhury S, Banerjee P, et al. Homeopathic remedy for arsenic toxicity?: Evidence-based findings from a randomized placebo controlled double blind human trial. Sci Tot Environ 2007; DOI: 10.1016/j.scitotenv.06.001.